State of the Industry Webinar

Calling the Shots: The State of the Covid-19 Vaccine Rollout

January 21, 2021 |  10am EST | 3pm GMT

The worldwide endeavor to create an effective Covid-19 vaccine has been a high profile area of focus for a host of pharmaceutical and biotech companies over the last year. Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson, among others, have been furiously working to develop and simultaneously manufacture a safe and effective vaccine for the pandemic that roiled the world and its economies.

HSBC’s Head of Global Healthcare Research, Dr. Stephen McGarry, will join Visible Alpha’s Research & Innovation Lab to discuss the companies at the center of the rollout of Covid-19 vaccines. This webinar will explore HSBC’s view on the state of play and expectations around the rollout of the vaccines, as well as Visible Alpha’s insights into the market’s quantitative expectations.

Join us on January 21 for a one-hour discussion on:

  • The state of play and expectations for Covid-19 vaccines from PFE and  BNTX, MRNA, AZN and JNJ
  • Uncertainties and analyst disagreements
  • Rollout considerations, distribution logistics and updated timings
  • If and how new Covid-19 variants are changing the strategy and the vaccine game plan

Following the discussion will be an open Q&A.

Steven McGarry headshot


Dr. Stephen McGarry, Managing Director, Head of Global Healthcare Research, HSBC

Dr. Stephen McGarry joined HSBC in 2015, covering European pharmaceutical stocks, having previously worked at other major investment banks and a healthcare fund. He has previously covered global pharmaceutical and biotechnology stocks. He has a First Class Honours Degree in Pharmacology from the University of Glasgow and a PhD in Pharmacology from the National Heart and Lung Institute.

Scott Rosen - Visible Alpha (1)

Scott Rosen, Founder and Chief Research & Innovation Officer, Visible Alpha

Scott Rosen is Visible Alpha’s Founder and Chief Research & Innovation officer, responsible for driving the company’s vision and transformational services. Scott has been a leader at the intersection of investment research and technology for more than 30 years. After starting his career as a sell-side analyst and Director of Research, Scott founded Trapeze, one of the first electronic research distribution platforms, in the early 1990’s. Scott went on to be Director of Research for I/B/E/S, a senior executive at Thomson Financial, where he ran the First Call research business among other roles, and entrepreneur-in-residence for He holds a B.A. Honors degree in Economics from Texas A&M University.


Philip Harrison, Director of Research, Visible Alpha

Philip Harrison is Senior Vice President and Director of Research at Visible Alpha, overseeing the firm’s research and data policies, while also helping guide the buy-side and sell-side user experience for the Visible Alpha Insights product. Previously, Philip was co-founder of Lusight Research, an independent research and technology firm focused on emerging markets, overseeing the firm’s technology and research initiatives in accounting, forecasting and valuation methodologies. He was also a senior equity and credit analyst at ING Barings, Duff & Phelps and UBS Warburg. Philip holds a B.S. in Economics from University of California, Riverside.

More From Visible Alpha

Bank industry ebook cover

Visible Alpha’s Guide to Commercial Bank KPIs for Investment Professionals

Visible Alpha worked with partners and clients to determine the key commercial bank metrics that will aid market participants in identifying banking trends and the future performance of commercial banks.


Read Full Analysis


Forecasting the Global Business Impact and Recovery from Covid-19

By combining the forecasts of over 4,300  analysts on thousands of public companies around the world, Visible Alpha created a mosaic of market expectations for the global economy over the next two years.

Explore Data


Missing Out: Why access to real-time analyst model revisions matters

Using Visible Alpha’s data, we set out to understand when and how often analysts revise estimates across companies in  a fiscal quarter and  how these revisions impacted point-in-time and daily consensus data.

Download Study